Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Nature Reviews. Drug Discovery
|
April 13, 2012
Stephen Frye. Interview by Asher Mullard
Stephen Frye
Molecular Pharmacology
|
November 15, 2012
Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules
Pilar Blancafort, Jian Jin, Stephen Frye
RSC Medicinal Chemistry
|
December 23, 2022
The future of chemical probes is diversity
Susanne Müller, Stephen Frye, Jonathan Baell
Nature Reviews. Drug Discovery
|
June 2, 2011
US academic drug discovery
Stephen Frye, Marina Crosby, Teresa Edwards, et al.
Nature Reviews. Drug Discovery
|
November 1, 2013
Bringing together the academic drug discovery community
Barbara S Slusher, P Jeffrey Conn, Stephen Frye, et al.
Journal of Medicinal Chemistry
|
May 5, 2022
Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected?
Stefan Laufer, Jürgen Bajorath, Matthias Gehringer, et al.
Journal of the American Chemical Society
|
March 25, 2011
Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in L3MBTL1
Cen Gao, J Martin Herold, Dmitri Kireev, et al.
Plos Pathogens
|
September 14, 2018
Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency
Sharon E Hopcraft, Samantha G Pattenden, Lindsey I James, et al.
Biochemical Pharmacology
|
February 11, 2021
MerTK activity is not necessary for the proliferation of glioblastoma stem cells
Monira Hoque, Siu Wai Wong, Ariadna Recasens, et al.
Oncotarget
|
March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
Alisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Nature Reviews. Drug Discovery
|
April 13, 2012
Stephen Frye. Interview by Asher Mullard
Stephen Frye
Molecular Pharmacology
|
November 15, 2012
Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules
Pilar Blancafort, Jian Jin, Stephen Frye
RSC Medicinal Chemistry
|
December 23, 2022
The future of chemical probes is diversity
Susanne Müller, Stephen Frye, Jonathan Baell
Nature Reviews. Drug Discovery
|
June 2, 2011
US academic drug discovery
Stephen Frye, Marina Crosby, Teresa Edwards, et al.
Nature Reviews. Drug Discovery
|
November 1, 2013
Bringing together the academic drug discovery community
Barbara S Slusher, P Jeffrey Conn, Stephen Frye, et al.
Journal of Medicinal Chemistry
|
May 5, 2022
Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected?
Stefan Laufer, Jürgen Bajorath, Matthias Gehringer, et al.
Journal of the American Chemical Society
|
March 25, 2011
Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in L3MBTL1
Cen Gao, J Martin Herold, Dmitri Kireev, et al.
Plos Pathogens
|
September 14, 2018
Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency
Sharon E Hopcraft, Samantha G Pattenden, Lindsey I James, et al.
Biochemical Pharmacology
|
February 11, 2021
MerTK activity is not necessary for the proliferation of glioblastoma stem cells
Monira Hoque, Siu Wai Wong, Ariadna Recasens, et al.
Oncotarget
|
March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
Alisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
Page
of 2